

1646
JFW



WON/SLR:dm 09/29/04 6235-62514-01 314413

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Matsumoto et al.

Application No. 10/088,726

Filed: October 1, 2002

Confirmation No. 6930

For: NOVEL GUANOSINE TRIPHOSPHATE-BINDING PROTEIN-COUPLED RECEPTORS, GENES THEREOF AND PRODUCTION AND USE OF SAME

Examiner: Nirmal S. Basi

Art Unit: 1646

Attorney Reference No. 6235-62514-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Date Mailed September 29, 2004

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.


This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this IDS.

If the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

OCT 01 2004

Attorney Docket Number	6235-62514-01
Application Number	10/088,726
Filing Date	October 1, 2002
First Named Inventor	Matsumoto
Art Unit	1646
Examiner Name	Nirmal S. Basi

U.S. PATENT DOCUMENTS

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/18206 A1	15.03.2001	Lexicon Genetics Incorporated
		WIPO	WO 01/48015 A2, A3	05.07.2001	Pharmacia & Upjohn Company

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		EMBL Accession No. AC005853 (1999).
		Gupte et al., "Elucidation of Signaling Properties of Vasopressin Receptor-Related Receptor 1 by Using the Chimeric Receptor Approach," <i>PNAS</i> 101:1508-1513 (2004).
		Laitinen et al., "Characterization of a Common Susceptibility Locus for Asthma-Related Traits," <i>Science</i> 304:300-304 (2004).
		Marchese et al., "Novel GPCRs and Their Endogenous Ligands: Expanding the Boundaries of Physiology and Pharmacology," <i>Trends Pharmacol. Sci.</i> 20:370-375 (1999).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.